Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt.
Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt; Centre for Catalysis Research and Innovation, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ontario K1N6N5, Canada.
Bioorg Chem. 2021 Jul;112:104965. doi: 10.1016/j.bioorg.2021.104965. Epub 2021 May 5.
Thirty-five new colchicine binding site inhibitors have been designed and synthesized based on the 1,2,4-triazin-3(2H)-one nucleus. Such molecules were synthesized through a cascade reaction between readily accessible α-amino ketones and phenyl carbazate as a masked N-isocyanate precursor. The synthesized derivatives are cisoid restricted combretastatin A4 analogues containing 1,2,4-triazin-3(2H)-one in place of the olefinic bond, and they have the same essential pharmacophoric features of colchicine binding site inhibitors. The synthesized compounds were evaluated in vitro for their antiproliferative activities against a panel of three human cancer cell lines (MCF-7, HepG-2, and HCT-116), using colchicine as a positive control. Among them, two compounds 5i and 6i demonstrated a significant antiproliferative effect against all cell lines with IC ranging from 8.2 - 18.2 µM. Further investigation was carried out for the most active cytotoxic agents as tubulin polymerization inhibitors. Compounds 5i and 6i effectively inhibited microtubule assembly with IC values ranging from 3.9 to 7.8 µM. Tubulin polymerization assay results were found to be comparable with the cytotoxicity results. The cell cycle analysis revealed significant G2/M cell cycle arrest of the analogue 5i in HepG-2 cells. The most active compounds 4i, 4j, 5 g, 5i and 6i did not induce significant cell death in normal human lung cells Wl-38, suggesting their selectivity against cancer cells. Also, These compounds upregulated the level of active caspase-3 and boosted the levels of the pro-apoptotic protein Bax by five to seven folds in comparison to the control. Moreover, apoptosis analyses were conducted for compound 5i to evaluate its apoptotic potential. Finally, in silico studies were conducted to reveal the probable interaction with the colchicine binding site. ADME prediction study of the designed compounds showed that they are not only with promising tubulin polymerization inhibitory activity but also with favorable pharmacokinetic and drug-likeness properties.
基于 1,2,4-三嗪-3(2H)-酮核,设计并合成了 35 种新型秋水仙碱结合位点抑制剂。这些分子是通过 readily accessible α-氨基酮和苯甲脒作为掩蔽的 N-异氰酸酯前体之间的级联反应合成的。合成的衍生物是顺式受限的 combretastatin A4 类似物,其中 1,2,4-三嗪-3(2H)-酮代替了双键,并且具有秋水仙碱结合位点抑制剂的相同基本药效特征。合成的化合物在体外对三种人癌细胞系(MCF-7、HepG-2 和 HCT-116)的增殖活性进行了评估,以秋水仙碱作为阳性对照。其中,两种化合物 5i 和 6i 对所有细胞系均表现出显著的增殖抑制作用,IC 范围为 8.2-18.2µM。对最具活性的细胞毒性剂作为微管蛋白聚合抑制剂进行了进一步研究。化合物 5i 和 6i 有效地抑制微管组装,IC 值范围为 3.9-7.8µM。微管蛋白聚合测定结果与细胞毒性结果相当。细胞周期分析显示类似物 5i 在 HepG-2 细胞中显著的 G2/M 细胞周期阻滞。最具活性的化合物 4i、4j、5g、5i 和 6i 对正常人类肺细胞 Wl-38 没有引起明显的细胞死亡,表明它们对癌细胞的选择性。此外,这些化合物使活性 caspase-3 水平上调,并使促凋亡蛋白 Bax 的水平提高了五到七倍与对照相比。此外,还对化合物 5i 进行了凋亡分析以评估其凋亡潜力。最后,进行了计算机模拟研究以揭示与秋水仙碱结合位点的可能相互作用。设计化合物的 ADME 预测研究表明,它们不仅具有有希望的微管蛋白聚合抑制活性,而且具有良好的药代动力学和类药性特性。